Division of CSL Ltd.
Latest From CSL Behring
Analysts said Grifols is poised for profit margin growth after the US FDA approved its first 20% subcutaneous immunoglobulin, Xembify, for treating primary immunodeficiencies.
With only seven letters last year, Office of Prescription Drug Promotion appears to be continuing its enforcement retrenchment as agency reconsiders its approach to Rx communications.
The Japanese pharmaceutical companies will work with the Global Antibiotic Research and Development Partnership on screening targets for utility against WHO-listed priority pathogens. Avacta and LG Chem collaborate around the former’s Affimer technology.
Dutch rare disease company Pharming talked to Scrip about turning a profit for the first time in the company’s history, finally restocking the pipeline in potentially blockbuster indications, and turning its attention back to Pompe disease after 20 years in the cold.
- Therapeutic Areas
- ZLB Central Laboratory
- ZLB Bioplasma AG
- ZLB Behring
- North America
- Parent & Subsidiaries
- CSL Ltd.
- Senior Management
Paul Perreault, CEO
David Lamont, CFO
Andrew Cuthbertson, PhD, Dir., R&D & CSO
Alan Wills, SVP, Strategy & Bus. Dev.
- Contact Info
Phone: (41)(610) 878-4000
1020 First Ave.
P.O. Box 61501 King of Prussia, PA 19406-0901
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.